Nilotinib Eg (Nilotinib)

Nilotinib is a targeted therapy that acts on the BCR‑ABL tyrosine‑kinase pathway in chronic myeloid leukemia.

• Chronic myeloid leukemia (chronic phase): improves hematologic and cytogenetic response in adult patients.
• Chronic myeloid leukemia (accelerated phase): helps achieve disease control and delay progression.
• Chronic myeloid leukemia (blast phase): used as part of combination regimens to reduce leukemic burden.

• Nilotinib selectively inhibits the BCR‑ABL tyrosine kinase, a fusion protein that drives uncontrolled proliferation of leukemic cells. By binding to the ATP‑binding site of the kinase, it blocks downstream signaling cascades, leading to reduced cell growth, induction of apoptosis, and suppression of the malignant clone in chronic myeloid leukemia.

Common side effects are generally mild to moderate and may resolve with continued therapy.

Common Side Effects

• Nausea
• Diarrhea
• Rash or skin irritation
• Headache
• Fatigue
• Muscle pain or cramps

Serious or Rare Side Effects

• QT interval prolongation and cardiac arrhythmias
• Arterial occlusive events (e.g., peripheral vascular disease)
• Pancreatitis
• Severe hepatic injury
• Stevens‑Johnson syndrome or toxic epidermal necrolysis
• Tumor lysis syndrome

Nilotinib requires careful monitoring and specific precautions to ensure safe use.

• Dose adjustment in hepatic impairment: reduce dose in patients with moderate to severe liver dysfunction.
• Monitor cardiac function: obtain baseline ECG and repeat periodically to detect QT prolongation.
• Avoid concomitant QT‑prolonging drugs: co‑administration may increase risk of arrhythmia.
• Regular blood count monitoring: assess for cytopenias during treatment.
• Pregnancy and lactation: safety unknown; avoid use unless benefits outweigh potential risks.
• Store at room temperature: keep in the original container, protect from moisture and light.

Nilotinib interacts with several drug classes that can alter its plasma concentration or increase toxicity.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may raise nilotinib levels and heighten adverse‑event risk.
• QT‑prolonging agents (e.g., amiodarone, fluoroquinolones): additive effect on cardiac repolarization.
• Antacids containing aluminum or magnesium: can reduce nilotinib absorption if taken simultaneously.

Moderate Interactions (Monitor Closely)

• CYP3A4 inducers (e.g., rifampin, carbamazepine): may lower nilotinib exposure, reducing efficacy.
• Warfarin: nilotinib can increase INR; monitor coagulation parameters.
• Statins metabolized by CYP3A4 (e.g., simvastatin, lovastatin): higher risk of myopathy; consider dose adjustment or alternative lipid‑lowering therapy.